We provide you with 20 years of free, institutional-grade data for FNCH stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of FNCH. Explore the full financial landscape of FNCH stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-05-10 | 0001733257 | FNCH | 10-Q | Url |
| 2024-03-25 | 0001733257 | FNCH | 10-K | Url |
| 2023-11-08 | 0001733257 | FNCH | 10-Q | Url |
| 2023-08-10 | 0001733257 | FNCH | 10-Q | Url |
| 2023-05-10 | 0001733257 | FNCH | 10-Q | Url |
| 2023-03-23 | 0001733257 | FNCH | 10-K | Url |
| 2022-11-10 | 0001733257 | FNCH | 10-Q | Url |
| 2022-08-11 | 0001733257 | FNCH | 10-Q | Url |
| 2022-05-16 | 0001733257 | FNCH | 10-Q | Url |
| 2022-03-31 | 0001733257 | FNCH | 10-K | Url |
| 2021-11-10 | 0001733257 | FNCH | 10-Q | Url |
| 2021-08-10 | 0001733257 | FNCH | 10-Q | Url |
| 2021-05-13 | 0001733257 | FNCH | 10-Q | Url |
| 2021-02-26 | 0001733257 | FNCH | S-1 | Url |
Finch Therapeutics Group, Inc(NASDAQ:FNCH) 
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the t...
Share this website to your friends
The information provided in this report about FNCH stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.